Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.

Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.

Clin Cancer Res. 2008 May 1;14(9):2673-80. doi: 10.1158/1078-0432.CCR-07-1046.

2.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391.

PMID:
19380449
3.

Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.

Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A.

J Clin Oncol. 2006 Aug 1;24(22):3623-8.

PMID:
16877730
4.

Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.

Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T.

Mol Carcinog. 2008 Jun;47(6):446-57.

PMID:
18058806
5.

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L.

Curr Med Chem. 2007;14(19):2009-23. Review.

PMID:
17691943
6.

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.

Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB.

J Clin Oncol. 2009 Jan 10;27(2):227-34. doi: 10.1200/JCO.2007.13.7083.

PMID:
19064988
7.
8.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
9.

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.

Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y.

Eur J Cancer. 2006 Mar;42(5):629-35.

PMID:
16464571
10.
11.

Activation of PI3K/Akt signaling and hormone resistance in breast cancer.

Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y.

Breast Cancer. 2006;13(2):137-44.

12.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

13.

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

Albert JM, Kim KW, Cao C, Lu B.

Mol Cancer Ther. 2006 May;5(5):1183-9.

14.

Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.

Mungamuri SK, Yang X, Thor AD, Somasundaram K.

Cancer Res. 2006 May 1;66(9):4715-24.

15.

Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.

Chollet P, Abrial C, Tacca O, Mouret-Reynier MA, Leheurteur M, Durando X, Curé H.

Clin Breast Cancer. 2006 Oct;7(4):336-8.

PMID:
17092402
16.

The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.

Fulda S.

Curr Cancer Drug Targets. 2009 Sep;9(6):729-37. Review.

PMID:
19754357
17.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.

J Clin Oncol. 2009 Mar 20;27(9):1382-7. doi: 10.1200/JCO.2008.16.8849.

PMID:
19224856
18.

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.

Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.

Expert Opin Investig Drugs. 2009 Sep;18(9):1333-49. doi: 10.1517/14728220903136775. Review.

PMID:
19678801
19.

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.

Clin Cancer Res. 2005 Jul 15;11(14):5319-28.

20.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.

Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285.

Items per page

Supplemental Content

Support Center